Yazar "Deveci, Ozcan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Prognostic significance of transforming growth factor-beta-1 in chronic hepatitis C virus infection
    (Academic Journals, 2012) Deveci, Ozcan; Agalar, Canan; Demirdal, Tuna; Demirturk, Nese; Yula, Erkan; Tekin, Alicem; Kilic, Dilek
    Interferon treatment in hepatitis C virus (HCV) infection is expensive and has various adverse effects. Some markers may help in making decision to stop or maintain the treatment. The aim of this study was to evaluate the effectiveness of serum transforming growth factor beta-1 (TGF-beta 1) in assessing outcome of interferon treatment in patients with HCV infection. Twelve patients with chronic HCV infections included in the study as treatment group [Treatment group: anti-HCV (+), HCV RNA (+)] and 12 patients with anti-HCV positive, HCV-RNA negative and normal liver function tests included as control group. All patients in the treatment group were administered with peginterferon and ribavirin for 24 weeks. HCV-RNA levels were determined by realtime-PCR and TGF-beta 1 levels were measured with ELISA methods, at the beginning and 24th week of the treatment. Mann-Whitney U Test and Wilcoxon Test were used to compare variables within and between groups. Median age and male/female ratios were 46 years and 5/7, and 45 years and 3/9 for treatment groups and control group, respectively. Although no difference was found in TGF-beta 1 levels at the beginning of the treatment between groups (p>0.05), significantly decreased TGF-beta 1 levels were observed following 24 weeks of interferon treatment in treatment group (p=0.015). Despite limited number of patients, our data suggested that, TGF-beta 1 levels may be used as a prognostic marker for effectiveness of interferon treatment in patients with hepatitis C virus infection.
  • Küçük Resim
    Öğe
    Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey
    (Natl Inst Infectious Diseases, 2016) Gul, Serdar; Kuscu, Ferit; Aydemir, Hande; Ozturk, Dogan Baris; Deveci, Ozcan; Duygu, Fazilet; Aslan, Emel
    The aim of this study was to investigate the incidence of acute kidney injury (AKI) and risk factors due to colistin use in patients infected with multidrug-resistant pathogens. This multicenter, retrospective, observational study was conducted in Turkey, at 5 different research and university hospitals. Cox regression analyses were performed, to determine independent predictors of AKI. From April 2012 to July 2014, a total of 216 patients aged between 18-94 years, treated with colistimethate sodium (CMS) were included in the study. The mean age of the patients was 60.3 +/- 20.1 years. The overall incidence of AKI was 34.3% (74/216) at any time during treatment. Concomitant use of loop diuretics, baseline creatinine level, and CMS dosage were independently associated with AKI. According to our results, patients with higher baseline creatinine levels, or patients who had to use concomitant loop diuretics may need to be monitored more closely, and dose adjustment should be done promptly. More comprehensive studies are, however, still needed to evaluate the efficacy of low-dose colistin since higher doses tend to increase the risk of AKI.